IP Library Granted Patent US 11,857,557
Granted Patent B2
US 11,857,557 · App. 17/038,494 · Granted Jan 2, 2024

Oral dissolvable film containing vitamin D3

Inventors: Maribel Espinoza (Oxnard, CA); Jose Bernardo (Oxnard, CA)
A61K31/593A61K9/0056A61K47/10A61K47/22A61K47/26A61K47/32A61K47/38A61K47/44
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,857,557
App. No.
17/038,494
Granted
Jan 2, 2024
Kind
B2
Abstract

The present invention relates to an oral dissolvable film (ODF) containing an active ingredient (e.g., vitamin D) that is, outside of the ODF, relatively unstable to at least one of heat, light, moisture, and oxygen. The present invention also relates to methods of manufacturing and using the same.

Claims (149)

1. A method of delivering cholecalciferol (vitamin D 3 ) to a human subject in need thereof, the method comprising orally administering to the human subject an oral dissolvable film comprising:

(i) water;

(ii) sodium carboxymethyl cellulose (Na CMC);

(iii) polyvinylpyrrolidone (PVP);

(iv) natural deodorized cocoa butter, present in 4.53±0.5 wt. % of the oral dissolvable film;

(v) glycerin;

(vi) polysorbate 80;

(vii) microcrystalline cellulose (MCC);

(viii) vitamin E;

(ix) a.scorbyl palmitate;

(x) vitamin D 3 ;

(xi) optionally flavoring agent;

(xii) optionally sweetener; and

(xiii) optionally coloring agent, wherein one oral dissolvable film is administered to the subject once per week.

2. The method of claim 1 , wherein upon orally administering to the human subject the oral dissolvable film, the cholecalciferol (vitamin D 3 ) is delivered enterally.

3. The method of claim 1 , wherein the oral dissolvable film is administered to the subject to prevent vitamin D deficiency, to treat vitamin D deficiency, or a combination thereof.

4. The method of claim 1 , wherein the oral dissolvable film comprises the water as a solvent, and is present in 8.00±3 wt. % of the oral dissolvable film.

5. The method of claim 1 , wherein the oral dissolvable film comprises the sodium carboxymethyl cellulose as a binder, and is present in 19.19±2 wt. % of the oral dissolvable film.

6. The method of claim 1 , wherein the oral dissolvable film comprises the polyvinylpyrrolidone, as a thickening agent, and is present in 11.71±1 wt. % of the oral dissolvable film.

7. The method of claim 1 , wherein the oral dissolvable film comprises the glycerin as a plasticizer, and is present in 9.16±1.5 wt. % of the oral dissolvable film.

8. The method of claim 1 , wherein the oral dissolvable film comprises the polysorbate 80 as an emulsifier, and is present in 7.32±1 wt. % of the oral dissolvable film.

9. The method of claim 1 , wherein the oral dissolvable film comprises the microcrystalline cellulose (MCC) as a filler, and is present in 9.27±1.5 wt. % of the oral dissolvable film.

10. The method of claim 1 , wherein the oral dissolvable film comprises the vitamin E as an antioxidant, and is present as vitamin E oil in 9.20±1.5 wt. % of the oral dissolvable film.

11. The method of claim 1 , wherein the oral dissolvable film comprises the ascorbyl palmitate as an antioxidant, and is present in 0.05±0.01 wt. % of the oral dissolvable film.

12. The method of claim 1 , wherein the oral dissolvable film comprises vitamin D 3 in an amount of 1.95±0.3 wt. % of the oral dissolvable film.

13. The method of claim 1 , wherein the oral dissolvable film comprises vitamin D 3 in an amount of 50K±10K IU.

14. The method of claim 1 , wherein the oral dissolvable film comprises vitamin D 3 in an amount of 40K±10K IU.

15. The method of claim 1 , wherein the oral dissolvable film comprises at least one of mountain berry and natural & artificial mixed berry as a flavoring agent, and is present in an aggregate amount of 17.27±2.2 wt. % of the oral dissolvable film.

16. The method of claim 1 , wherein the oral dissolvable film comprises sucralose as a sweetener, and is present in 2.33±0.5 wt. % of the oral dissolvable film.

17. The method of claim 1 , wherein the oral dissolvable film comprises FD&C Red #40 as a coloring agent, and is present in 0.01±0.001 wt. % of the oral dissolvable film.

18. The method of claim 1 , wherein the oral dissolvable film comprises

Ingredient

Amount (wt. %) in hydrous strip

Water

8.00 ± 3

wt. %

Sodium Carboxymethyl Cellulose

19.19 ± 2

wt. %

(Na CMC)

Polyvinylpyrrolidone (PVP)

11.71 ± 1

wt. %

Natural Deodorized Cocoa Butter

4.53 ± 0.5

wt. %

Glycerin (99.7% USP)

9.16 ± 1.5

wt. %

Polysorbate 80, NF

7.32 ± 1

wt. %

Mountain Berry

9.61 ± 1.5

wt. %

Sucralose USP/NF

2.33 ± 0.5

wt. %

Microcrystalline Cellulose (MCC)

9.27 ± 1.5

wt. %

Vitamin E Oil 1000 IU

9.20 ± 1.5

wt. %

Ascorbyl Palmitate

0.05 ± 0.01

wt. %

Vitamin D 3

1.95 ± 0.3

wt. %

Natural & Artificial Mixed Berry

7.66 ± 0.7

wt. %

FD&C Red #40

0.01 ± 0.001

wt. %

Total

100.00

wt. %.

19. The method of claim 1 , wherein the oral dissolvable film comprises

Ingredient

Amount (wt. %) in hydrous strip

Water

8.00

wt. %

Sodium Carboxymethyl Cellulose

19.19

wt. %

(Na CMC)

Polyvinylpyrrolidone (PVP)

11.71

wt. %

Natural Deodorized Cocoa Butter

4.53

wt. %

Glycerin (99.7% USP)

9.16

wt. %

Polysorbate 80, NF

7.32

wt. %

Mountain Berry

9.61

wt. %

Sucralose USP/NF

2.33

wt. %

Microcrystalline Cellulose

9.27

wt. %

(MCC)

Vitamin E Oil 1000 IU

9.20

wt. %

Ascorbyl Palmitate

0.05

wt. %

Vitamin D 3

1.95

wt. %

Natural & Artificial Mixed Berry

7.66

wt. %

FD&C Red #40

0.01

wt. %

Total

100.00

wt. %.

20. The method of claim 1 , wherein the oral dissolvable film has a thickness of 0.130±0.004 mm.

21. The method of claim 1 , wherein the oral dissolvable film has a water content of 8±5 wt. %.

22. The method of claim 1 , wherein the oral dissolvable film has a. disintegration time of 5 to 40 seconds, upon application to a surface of the oral cavity.

23. The method of claim 1 , wherein the oral dissolvable film has a content uniformity such that the vitamin D 3 ranges from about 90-110%, with the standard deviation of up to about 6%.

24. The method of claim 1 , wherein the oral dissolvable film has a mass of 80±15 mg.

25. The method of claim 1 , wherein the oral dissolvable film is administered to a subject: (i) afflicted with deficiency of vitamin D; (ii) at risk of deficiency of vitamin D; (iii) undergoing chemotherapy; (iv) undergoing treatment for cancer; (v) undergoing bone marrow transplant; or any combination thereof.

26. The method of claim 1 , wherein the oral dissolvable film comprises:

(i) water;

(ii) sodium carboxymethyl cellulose (Na CMC);

(iii) polyvinylpyrrolidone (PVP);

(iv) natural deodorized cocoa butter, present in 4.53±0.5 wt. % of the oral dissolvable film;

(v) glycerin;

(vi) polysorbate 80;

(vii) microcrystalline cellulose (MCC);

(viii) vitamin E;

(ix) ascorbyl palmitate;

(x) vitamin D 3 ;

(xi) flavoring agent;

(xii) sweetener; and

(xiii) coloring agent.

Assignments (5)
LIEN Recorded Jan 28, 2025
From: CURE PHARMACEUTICAL, INC.
To: CUREX PHARMACEUTICAL MEXICO S.A.P.I. DE C.V.
Reel/Frame 070027/0201 →
CHANGE OF NAME Recorded Jul 17, 2023
From: TF TECH VENTURES, INC.
To: CURE PHARMACEUTICAL, INC.
Reel/Frame 064286/0450 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY NAME WHICH SHOULD READ TF TECH VENTURES, INC. AND NOT TF TECH VENTURES PREVIOUSLY RECORDED AT REEL: 060598 FRAME: 0016. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jul 12, 2023
From: CURE PHARMACEUTICAL CORPORATION
To: TF TECH VENTURES, INC.
Reel/Frame 064256/0361 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2022
From: CURE PHARMACEUTICAL CORPORATION
To: TF TECH VENTURES
Reel/Frame 060598/0016 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2022
From: ESPINOZA, MARIBEL; BERNARDO, JOSE
To: CURE PHARMACEUTICAL CORPORATION
Reel/Frame 059884/0768 →
Continuity (2)
Provisional Application 62907855 · Sep 30, 2019
Related Publication 20210145849A1 · May 20, 2021